Osteoarthritis Management R Gunadi

44
Rachmat Gunadi Wachjudi Lahir di Garut, 16-1-1955 Pendidikan SD-SMA : Garut Dokter umum: FK UNSRI Palembang Spesialis1: FK UNPAD Bandung Spesialis2: FK UI Jakarta Clinical Rheumatology & Osteoporosis training Arthritis foundation of WA Pekerjaan: Ka Div Reumatologi Dep I Peny Dalam RS Dr Hasan Sadikin Organisasi Profesi IDI, IRA, PAPDI, PEROSI, PERALMUNI

description

an overview of Osteoarthritis management according to OARSI, ACR and EULAR guideline

Transcript of Osteoarthritis Management R Gunadi

Page 1: Osteoarthritis Management R Gunadi

Rachmat Gunadi Wachjudi

Lahir di Garut, 16-1-1955Pendidikan SD-SMA : Garut Dokter umum: FK UNSRI

Palembang Spesialis1: FK UNPAD Bandung Spesialis2: FK UI Jakarta Clinical Rheumatology &

Osteoporosis training Arthritis foundation of WA

Pekerjaan: Ka Div Reumatologi Dep I Peny

Dalam RS Dr Hasan SadikinOrganisasi Profesi IDI, IRA, PAPDI, PEROSI,

PERALMUNI

Page 2: Osteoarthritis Management R Gunadi

The Management of Osteoarthritis

Without Compromising the Patient's Safety

Rachmat Gunadi Wachjudi

Perhimpunan Reumatologi IndonesiaBandung

Page 3: Osteoarthritis Management R Gunadi

OA in Primary Care

■ Most patients with OA are managed in Primary Care

■ Overall, musculoskeletal problems account for 10-30 % of General Practice consultations4

■ GPs have an opportunity to optimise patient care in OA

Page 4: Osteoarthritis Management R Gunadi

Factors Implicated in the Development of OA

Cartilage breakdown

ObesityObesity

Anatomic abnormalities

Anatomic abnormalities

Microfractures and bony

remodeling

Microfractures and bony

remodeling

Loss of joint stability

Loss of joint stability

TraumaTrauma

AgingAging

Genetic and metabolic diseases

Genetic and metabolic diseases

InflammationInflammation

Immune system activity

Immune system activity

Compromised cartilage

Biophysical changes• Collagen network fracture• Proteoglycan unraveling

Biochemical changes• Inhibitors reduced

• Proteolytic enzymes increased

Abnormal stresses Abnormal cartilage

Mandelbaum B et al. Orthopedics. 2005;28(2 suppl):s207-s214.Adapted with permission from 2002 Medtronic Sofamor Danek, Basic Bone Biology.

Page 5: Osteoarthritis Management R Gunadi

EULAR Diagnostic Criteria for Knee OA (2010)

■ Based on review of studies from 1950-2008 and expert consensus

■ Focuses on clinical diagnosis: presence of three symptoms andthree signs correctly diagnoses 99% of cases

SymptomsSymptoms

1 Persistent knee pain √

2 Limited morning stiffness √

3 Reduced function √

SignsSigns

4 Joint crepitus √

5 Restricted movement √

6 Bony enlargement √

EULAR=European League Against Rheumatism.

Zhang W et al. Ann Rheum Dis. 2010;69(3):483-489.

Page 6: Osteoarthritis Management R Gunadi

Goals of OA Management:OARSI Recommendations

Reducejoint pain and

stiffness

Reduce physical disability

ImproveHRQoL

Educate patients

Limitprogression of joint damage

Knee and Hip OA: Goals of Treatment

HRQoL=health-related quality of life; OARSI=Osteoarthritis Research Society International.

Zhang W et al. Osteoarthritis Cartilage. 2008;16(2):137-162.

Maintain and improve joint

mobility

Page 7: Osteoarthritis Management R Gunadi

ACR 2000 Guidelines— Pharmacologic/Surgical Therapy

American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905-1915.

Mild to Moderate Pain

• Simple analgesics (eg, acetaminophen)

• OTC NSAIDs

• Topical creams

Moderate to Severe Pain

• Rx NSAIDs plus gastroprotective agent,or COX-2–selective inhibitors

AdditionalTherapies

• IA hyaluronans

• IA steroidsSurgical

Intervention

• Total knee replacement

Page 8: Osteoarthritis Management R Gunadi

EULAR guidelines

The 10 Keys

8Please see Full Prescribing Information available at this presentation.

Page 9: Osteoarthritis Management R Gunadi

Key principles5: EULAR guidelines

1. Treatment should be tailored to the patient

2. The relationship between the healthcare team and the patient should be a two-way process

3. Using tools can help to assess the patient’s pain and disability

4. Patient education has a significant impact on pain management

5. Treatment should be a combination of non-pharmacological and pharmacological measures

Page 10: Osteoarthritis Management R Gunadi

Management options5: EULAR guidelines

6. Non-pharmacological management strategies should be incorporated

7. Paracetamol and NSAIDs should be used as first-line pharmacotherapy

8. There is evidence to support the use of some symptomatic slow-acting drugs for OA (SYSADOA)

9. Corticosteroid intra-articular injections can be useful in acute exacerbations

10.Consider surgery in patients unresponsive to medical management

Page 11: Osteoarthritis Management R Gunadi

Key principle 1Patient-tailored treatment

■ OA is a long-term, chronic condition and has a considerable impact on quality of life

■ Treatment should: be tailored to the patient consider the individual patient’s needs in terms of both

functionality and of pain relief5

■ It is likely that each individual patient will have to try a number of management options before finding the combination which works best for them

Page 12: Osteoarthritis Management R Gunadi

Key principle 2 Doctor/patient relationship5

■ The patient should be an active partner in disease management

■ Involve the patient in treatment decisions and listen to their concerns

■ The patient is an expert in their disease: they know their pain better than anyone else and will have developed strategies to deal with it

Page 13: Osteoarthritis Management R Gunadi

Key principle 3Using tools

■ Tools can help to assess the patient’s pain and disability

■ Tools include: rating scales questionnaires pain diagrams

■ Using tools before and after treatment is also useful to determine whether treatment is working

Page 14: Osteoarthritis Management R Gunadi

Pain drawings

Mark the area on your body where you feel the described sensations

Use the appropriate symbol

Mark the areas of radiation

Include all affected areas

Numbness = = = =

Pins and needles ° ° ° ° ° ° Burning xxxxxxxx

Stabbing / / / / / / /

Page 15: Osteoarthritis Management R Gunadi

Rating scales ■ Visual analogue scale

No pain

Worst possible pain

• Pain intensity

0 No pain

1 Mild

2 Discomforting

3 Distressing

4 Horrible

5 Excruciating

Page 16: Osteoarthritis Management R Gunadi

Key principle 4Patient education

■ Studies suggest that education is around 20% as effective as NSAIDs, and can have a synergistic effect with other treatments

■ Patient information and self-management strategies can empower patients to take control of their arthritis

■ Effective education techniques include: individual education packs regular telephone calls group education patient coping skills spouse assisted coping skills training

Page 17: Osteoarthritis Management R Gunadi

Key principle 5Management options

■ Treatment should be a combination of non-pharmacological and pharmacological measures

■ Indirect evidence suggests non-pharmacological treatments offer additional benefits over and above treatment with NSAIDs and analgesics

Page 18: Osteoarthritis Management R Gunadi

Management option 6Non-pharmacological management

■ Life-style modification has an important role in management5,9

■ For example: weight loss exercise

– quadriceps strengthening– range of movement– general fitness– hydrotherapy

assistive devices (canes and frames) appropriate footwear, insoles

Page 19: Osteoarthritis Management R Gunadi

Management option 6 Non-pharmacological management

■ Little formal evidence to support complementary therapies, but some patients derive considerable benefit

■ Examples of complementary therapies include:Acupuncture Alexander techniqueAromatherapy ChiropracticHydrotherapy MassageOsteopathy ReflexologyTai chi

Page 20: Osteoarthritis Management R Gunadi

Management option 6 Non-pharmacological management

■ Self-management strategies can improve patients’ ability to manage their pain and disability of OA

■ Access to patient organisations and support groups which provide help and advice PERMARIKelompok Senam Ranca Badak

Page 21: Osteoarthritis Management R Gunadi

Management option 7Analgesia and NSAIDs

■ Use paracetamol as first-line therapy5

■ It is likely that the majority of patients will have already tried over-the-counter paracetamol5

■ In those patients with a poor response to paracetamol, NSAIDs should be considered5

■ At ‘the lowest effective dose for the shortest possible duration’. (EMEA 27 June 2005)

Page 22: Osteoarthritis Management R Gunadi

Management option 7 (1)COX-2 selective inhibitors

■ Consider in patients who may be at high risk of developing serious GI adverse events, and in whom an NSAID is clearly indicated10

■ High-risk patients include, those: aged 65 years and over, with a previous clinical history of gastroduodenal ulcer, GI

bleeding or gastroduodenal perforation. The use of even a COX-2 selective agent should be considered especially carefully in this situation,

taking concomitant medication(s) that are known to increase the likelihood of upper GI adverse events (eg corticosteroids, anti-coagulants)

Page 23: Osteoarthritis Management R Gunadi

Management option 7 (2)COX-2 selective inhibitors

June 2005 – The European Medicines Agency reviewed Cox-2 selective inhibitors, they concluded that:

– Cox-2 selective inhibitors (Celecoxib, Etoricoxib, Lumiracoxib, Parecoxib) will have stronger guidelines for prescription:– Cox-2s should not be prescribed to people with

ischaemic heart disease, cerebrovascular disease or peripheral arterial disease

– caution when prescribing Cox-2s to people with heart disease, hypertension, hyperlipidaemia (cholesterol), diabetes and smokers

Page 24: Osteoarthritis Management R Gunadi

Celecoxib Efficacy in Osteoarthritis

Page 25: Osteoarthritis Management R Gunadi

McKenna F et al. Scand J Rheumatol 2001;30:11–18.VAS=visual analogue scale.

Less P

ain

Patient’s Assessment of Pain (VAS): Mean change at week 6

Mea

n C

ha

ng

e (m

m)

*p=0.001 vs. placebo

placebo(n=200)

celecoxib100 mg BID(n=199)

diclofenac50 mg TID(n=199)

CELECOXIB vs. diclofenac:6-week Knee OA TrialMcKenna et al. 2001: Patient’s Assessment of Pain

Page 26: Osteoarthritis Management R Gunadi

McKenna F et al. Scand J Rheumatol. 2001;30:11-18.

American Pain Society (APS) Pain Measure:Worst Pain in the Past 24 Hours

Mean

Ch

an

ge in

Score p=0.05, active treatment vs.

placebo (days 1-7).

-4.0

-3.5

-3.0

-2.5

-2.0

-1.5

-1.0

-0.5

0.0Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7

placebo (n=200)

celecoxib 100 mg BID (n=199)

diclofenac 50 mg TID (n=199)

Less P

ain

CELECOXIB vs. diclofenac:6-week Knee OA TrialMcKenna et al. 2001: American Pain Society – Pain Measure

Page 27: Osteoarthritis Management R Gunadi

CelecoxibGastrointestinal Safety Profile

Page 28: Osteoarthritis Management R Gunadi

Silverstein FE et al. JAMA. 2000;284:1247-1255.

An

nu

aliz

ed in

cid

ence

(%

)(p

er N

o. o

f p

atie

nt-

year

s)

0

1

2

3

4

Upper GI ulcercomplications

Complications andsymptomatic ulcers

P=.09

P=.02

0.76%

1.45%

2.08%

3.54%

CLASS: UGI Ulcer Complications and Symptomatic Ulcers at 6 Months—All Patients

Nonspecific NSAIDs* (n=3981)

Celecoxib 400 mg BID(n=3987)

Page 29: Osteoarthritis Management R Gunadi

SUCCESS=Successive Celecoxib Efficacy and Safety Study in OA.*Celecoxib 200 mg/day or 400 mg/day; †Diclofenac 50 mg BID or naproxen 500 mg BID.Singh G et al. Presented at: EULAR; June 13-16, 2001; Prague, Czech Republic.

SUCCESS-1: UGI Ulcer Complications and Symptomatic Ulcers

0.1

0.8 1.0

2.1

0

1

2

3

4

Ulcer complications Complications andsymptomatic ulcers

RRR=87.5%P<.05

RRR=51.5%P<.05

An

nu

aliz

ed r

ate

(eve

nts

per

100

pat

ien

t-ye

ars)

Nonspecific NSAIDs† (n=4394)

Celecoxib*(n=8800)

Page 30: Osteoarthritis Management R Gunadi

Utilization of Gastroprotective Strategies by Presence of GI Risk Factors Among New NSAID Users

Sturkenboom et al. Rheumatology. 2003;42(suppl 3):iii23-iii31.

≥≥2 Risk Factors2 Risk Factors1 Risk Factor1 Risk Factor

86.6% 81.2%

0.1%0.1% 2.5%2.5% 10.8%10.8% 0.2%0.2% 4.0%4.0% 14.7%14.7%

Coxib aloneCoxib alone NSAID+GPANSAID+GPA Coxib+GPACoxib+GPA No gastroprotectionNo gastroprotection

Page 31: Osteoarthritis Management R Gunadi

CONDOR 2010

0.9

3.8

0

0.5

1

1.5

2

2.5

3

3.5

4

Pro

po

rtio

n o

f p

ati

en

ts %

celecoxib 200 mg BID (n=2238)

diclofenac SR 75 mg BID + omeprazole 20 mg OD (n=2246)P<0.0001

Chan FKL et al. Lancet 2010; DOI:10.1016/S0140-6736(10)60673-3

Patient with celecoxib has lower risk on gastrointestinal events than those with diclofenac SR + omeprazole

(20 events, 95% CI, (20 events, 95% CI, 0.5-1.3)0.5-1.3)

(81 events, 95% CI, 2.9-4.3)

Page 32: Osteoarthritis Management R Gunadi

CelecoxibCardiovascular Safety

Page 33: Osteoarthritis Management R Gunadi

CLASS: Thromboembolic CV AEsASA NonusersASA NonusersASA Users*ASA Users*

PP=.899=.899PP=.947=.947

00

0.50.5

1.01.0

1.51.5

2.02.0

2.52.5

3.03.0

3.53.5

4.54.5

5.05.0

4.04.0

00 4040 8080 120120 160160 200200 240240 280280 320320 360360

DaysDays

Celecoxib 400 mg bid (n=3105)Celecoxib 400 mg bid (n=3105)

NS-NSAIDs (n=3124)NS-NSAIDs (n=3124)

Celecoxib 400 mg bid (n=882)Celecoxib 400 mg bid (n=882)

NS-NSAIDs (n=857)NS-NSAIDs (n=857)

Pat

ien

ts (

%)

Pat

ien

ts (

%)

00 4040 8080 120120 160160 200200 240240 280280 320320 360360

DaysDays

00

0.50.5

1.01.0

1.51.5

2.02.0

2.52.5

3.03.0

3.53.5

4.54.5

5.05.0

4.04.0

White et al. White et al. Am J CardiolAm J Cardiol. 2002;89:425-430. . 2002;89:425-430. Data on file. Pfizer Inc., New York, NY; FDA Advisory Committee Briefing Document. Data on file. Pfizer Inc., New York, NY; FDA Advisory Committee Briefing Document. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf. Accessed January 12, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf. Accessed January 12, 2005.

Page 34: Osteoarthritis Management R Gunadi

Medi-Cal: NSAIDs and Risk for AMI

0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8

2,356,885 person-years of follow-up; 15,343 cases of AMI2,356,885 person-years of follow-up; 15,343 cases of AMI

OR for AMI (95% CI)OR for AMI (95% CI)

Singh et al. EULAR. 2005. Singh et al. EULAR. 2005.

0.83 (0.60-1.14); 0.83 (0.60-1.14); PP=.26=.26

0.99 (0.72-1.37); 0.99 (0.72-1.37); PP=.97=.97

1.08 (0.95-1.22); 1.08 (0.95-1.22); PP=.22=.22

1.09 (1.02-1.15); 1.09 (1.02-1.15); PP<.008<.008

1.11 (1.01-1.22); 1.11 (1.01-1.22); PP<.02<.02

1.32 (1.22-1.42); 1.32 (1.22-1.42); PP<.0001<.0001

1.37 (1.05-1.78); 1.37 (1.05-1.78); PP<.02<.02

1.41 (1.01-1.96); 1.41 (1.01-1.96); PP<.04<.04

1.71 (1.35-2.17); 1.71 (1.35-2.17); PP<.0001<.0001

1.00 (reference)1.00 (reference)

NabumetoneNabumetone

ValdecoxibValdecoxib

NaproxenNaproxen

CelecoxibCelecoxib

IbuprofenIbuprofen

RofecoxibRofecoxib

MeloxicamMeloxicam

SulindacSulindac

IndomethacinIndomethacin

Remote useRemote use

Page 35: Osteoarthritis Management R Gunadi

CelecoxibRenal & Hepar Safety Profile

Page 36: Osteoarthritis Management R Gunadi

Incidence of patients with treatment-related CV, renal, and hepatic AEs

1.71.1

4.1

5.2

0

1

2

3

4

5

6

CV / renal AE Hepatic AE

% P

atie

nts

celecoxib 200 mg OD diclofenac 50 mg BID

CELECOXIB vs. diclofenacDahlberg et al. 2009: CV / renal & hepatic AEs

One-year, randomized, multicentre, double-blind, parallel-group study to assess the AE-related discontinuation rate with celecoxib and diclofenac in elderly patients with OA.No p-values reported for related/not-related-to-treatment incidence. Significantly fewer patients in the celecoxib group than the diclofenac group experienced cardiovascular/renal AEs (70/458 vs. 95/458, p=0.039) or hepatic AEs (10/458 vs. 39/458, p<0.0001).Dahlberg LE et al. Scand J Rheumatol 2009;38:133-143.

Page 37: Osteoarthritis Management R Gunadi

Management option 8Symptomatic slow-acting drugs of OA

■ Symptomatic slow-acting drugs of OA (SYSADOA) glucosamine chondroitin hyaluronic acid

■ Supported by increasing evidence, although further research is still required

■ Given that these agents appear to be well tolerated and do show some benefit their use should be considered

Page 38: Osteoarthritis Management R Gunadi

Management option 9Corticosteroid injections

■ Corticosteroid intra-articular injections may be used in the management of patients with OA of the knee

■ Provide superior short-term efficacy (2-4 weeks) versus placebo

■ Recommended for acute exacerbations

Page 39: Osteoarthritis Management R Gunadi

Management option 10Surgery

■ Refer for orthopaedic evaluation if patient is disabled by OA or in pain unrelieved by medical management

■ Joint replacement can be very effective

■ Newer techniques such as metal-on-metal resurfacing are less invasive

■ Patients should be made aware of the risks and benefits of surgery

Page 40: Osteoarthritis Management R Gunadi

OA: Management Summary

• First: Be sure the pain is joint related (not a tendonitis or bursitis adjacent to joint)

• Initial treatment• Muscle strengthening exercises and

reconditioning walking program• Weight loss• Acetaminophen for pain relieve • Local heat/cold and topical agents• SYSADOA

Page 41: Osteoarthritis Management R Gunadi

OA: Management Summary (cont’d)

• Second-line approach• NSAIDs or COX-2 inhibs if acetaminophen fails• Intra-articular agents or lavage• Opioids

• Third-line • Arthroscopy• Osteotomy• Total joint replacement

Page 42: Osteoarthritis Management R Gunadi

Treatment Overview

Page 43: Osteoarthritis Management R Gunadi
Page 44: Osteoarthritis Management R Gunadi

Thank You